Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -229.48 Thousand USD | 22.91% |
| 2023 | -297.67 Thousand USD | 48.99% |
| 2022 | -583.58 Thousand USD | -21.92% |
| 2021 | -478.66 Thousand USD | -21.41% |
| 2020 | -394.24 Thousand USD | 76.94% |
| 2019 | -1.7 Million USD | -944.26% |
| 2018 | -163.68 Thousand USD | 55.85% |
| 2017 | -370.72 Thousand USD | -135.78% |
| 2016 | 1.03 Million USD | 262.93% |
| 2015 | -635.86 Thousand USD | 34.17% |
| 2014 | -965.9 Thousand USD | -213.55% |
| 2013 | -308.05 Thousand USD | -279.3% |
| 2012 | -81.21 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -52.72 Thousand USD | 26.53% |
| 2024 Q1 | -71.2 Thousand USD | -23.22% |
| 2024 Q4 | -33.78 Thousand USD | 35.94% |
| 2024 FY | -229.49 Thousand USD | 22.91% |
| 2024 Q2 | -71.76 Thousand USD | -0.79% |
| 2023 Q2 | -82.35 Thousand USD | 9.96% |
| 2023 FY | -297.67 Thousand USD | 48.99% |
| 2023 Q3 | -66.07 Thousand USD | 19.76% |
| 2023 Q1 | -91.46 Thousand USD | 43.07% |
| 2023 Q4 | -57.78 Thousand USD | 12.54% |
| 2022 Q1 | -122.7 Thousand USD | 50.74% |
| 2022 Q4 | -160.66 Thousand USD | 8.25% |
| 2022 Q2 | -125.1 Thousand USD | -1.95% |
| 2022 FY | -583.58 Thousand USD | -21.92% |
| 2022 Q3 | -175.11 Thousand USD | -39.98% |
| 2021 Q3 | -94.21 Thousand USD | -8.48% |
| 2021 Q4 | -249.07 Thousand USD | -164.35% |
| 2021 Q2 | -86.85 Thousand USD | -79.02% |
| 2021 FY | -478.66 Thousand USD | -21.41% |
| 2021 Q1 | -48.51 Thousand USD | 45.37% |
| 2020 FY | -394.24 Thousand USD | 76.94% |
| 2020 Q4 | -88.8 Thousand USD | 50.88% |
| 2020 Q1 | -66.95 Thousand USD | 14.05% |
| 2020 Q2 | -57.7 Thousand USD | 13.81% |
| 2020 Q3 | -180.78 Thousand USD | -213.3% |
| 2019 Q1 | -61.84 Thousand USD | -30.48% |
| 2019 FY | -1.7 Million USD | -944.26% |
| 2019 Q4 | -77.89 Thousand USD | 94.83% |
| 2019 Q3 | -1.5 Million USD | -2317.34% |
| 2019 Q2 | -62.34 Thousand USD | -0.81% |
| 2018 Q4 | -47.39 Thousand USD | -83.42% |
| 2018 Q3 | -25.84 Thousand USD | 25.18% |
| 2018 FY | -163.68 Thousand USD | 55.85% |
| 2018 Q1 | -55.9 Thousand USD | 41.22% |
| 2018 Q2 | -34.53 Thousand USD | 38.22% |
| 2017 Q1 | -114.35 Thousand USD | -108.02% |
| 2017 Q2 | -94.1 Thousand USD | 17.7% |
| 2017 Q3 | -67.16 Thousand USD | 28.63% |
| 2017 FY | -370.72 Thousand USD | -135.78% |
| 2017 Q4 | -95.1 Thousand USD | -41.61% |
| 2016 Q2 | -109.87 Thousand USD | 19.21% |
| 2016 FY | 1.03 Million USD | 262.93% |
| 2016 Q1 | -136.01 Thousand USD | -11.63% |
| 2016 Q4 | 1.42 Million USD | 1090.42% |
| 2016 Q3 | -143.96 Thousand USD | -31.03% |
| 2015 Q3 | -164 Thousand USD | 22.51% |
| 2015 Q2 | -211.63 Thousand USD | -1.56% |
| 2015 Q1 | -208.38 Thousand USD | 19.97% |
| 2015 FY | -635.86 Thousand USD | 34.17% |
| 2015 Q4 | -121.84 Thousand USD | 25.71% |
| 2014 Q2 | -242.68 Thousand USD | -29.54% |
| 2014 FY | -965.9 Thousand USD | -213.55% |
| 2014 Q3 | -273.51 Thousand USD | -12.7% |
| 2014 Q1 | -187.34 Thousand USD | -138.56% |
| 2014 Q4 | -260.37 Thousand USD | 4.8% |
| 2013 Q2 | -97.78 Thousand USD | -20.57% |
| 2013 Q3 | -50.64 Thousand USD | 48.21% |
| 2013 Q4 | -78.52 Thousand USD | -55.06% |
| 2013 FY | -308.05 Thousand USD | -279.3% |
| 2013 Q1 | -81.09 Thousand USD | 0.14% |
| 2012 Q2 | -17.38 Thousand USD | -2977.35% |
| 2012 FY | -81.21 Thousand USD | 0.0% |
| 2012 Q1 | -565.00 USD | 0.0% |
| 2012 Q4 | -81.21 Thousand USD | -2053.13% |
| 2012 Q3 | -3772.00 USD | 78.31% |
| 2011 FY | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 82.816% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 95.451% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 98.714% |
| Nascent Biotech, Inc. | -2.22 Million USD | 89.709% |
| Rebus Holdings, Inc. | -664 Thousand USD | 65.439% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.28% |
| Qrons Inc. | -643.67 Thousand USD | 64.348% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 41.092% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.587% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 44.766% |
| Skye Bioscience, Inc. | -13.67 Million USD | 98.321% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.68% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 104.669% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 12.318% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.697% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 91.949% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 85.06% |
| Mesoblast Limited | -84.14 Million USD | 99.727% |
| Marizyme, Inc. | -34.08 Million USD | 99.327% |
| Genus plc | 6.4 Million USD | 103.586% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 102.356% |
| Pharming Group N.V. | -4.87 Million USD | 95.297% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 88.448% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 75.361% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 97.252% |
| ContraFect Corporation | -56.88 Million USD | 99.597% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 94.962% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 83.631% |
| IMV Inc. | -38.67 Million USD | 99.407% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 91.658% |
| MultiCell Technologies, Inc. | -722.81 USD | -31649.146% |
| ONE Bio Corp. | 13.68 Million USD | 101.677% |
| Accustem Sciences Inc. | -3.74 Million USD | 93.875% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.611% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 52.493% |
| Q BioMed Inc. | -3.44 Million USD | 93.34% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 106.483% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 91.266% |
| Biomind Labs Inc. | -1 Million USD | 77.27% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.583% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 92.09% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 96.548% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 87.691% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -666.179% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 98.554% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 88.126% |
| GB Sciences, Inc. | -1.42 Million USD | 83.845% |
| Alpha Cognition Inc. | -9.7 Million USD | 97.636% |
| HST Global, Inc. | -140.9 Thousand USD | -62.863% |
| CSL Limited | 3.7 Billion USD | 100.006% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 79.6% |
| Halberd Corporation | -75.05 Thousand USD | -205.777% |
| Enzolytics Inc. | -2.14 Million USD | 89.32% |
| Agentix Corp. | -1.37 Million USD | 83.271% |
| Resverlogix Corp. | -12.74 Million USD | 98.2% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 92.757% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.946% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 78.019% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 92.139% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 85.47% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 93.26% |
| AVAX Technologies, Inc. | 6.69 Million USD | 103.429% |
| Zenith Capital Corp. | -8.94 Million USD | 97.434% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.945% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -1217.295% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 90.654% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -33.804% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 88.553% |
| Kadimastem Ltd | -3.04 Million USD | 92.452% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 76.68% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 81.729% |
| BioStem Technologies, Inc. | -7.77 Million USD | 97.05% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -26.449% |
| LadRx Corporation | -3.82 Million USD | 93.998% |
| Cell Source, Inc. | -4.32 Million USD | 94.694% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 66.593% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 66.593% |
| NovAccess Global Inc. | -2.46 Million USD | 90.697% |
| Affymax, Inc. | -15.04 Million USD | 98.475% |
| Itoco Inc. | -919.14 Thousand USD | 75.033% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 94.586% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 79.492% |
| Mobile Lads Corp. | -554.55 Thousand USD | 58.618% |
| CytoDyn Inc. | -18.05 Million USD | 98.729% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -811.744% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -4.275% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 59.363% |
| SYBLEU INC | -149.18 Thousand USD | -53.832% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 87.365% |
| International Stem Cell Corporation | -663 Thousand USD | 65.387% |
| Bioxytran, Inc. | -3.82 Million USD | 93.993% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -335.954% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -1028.25% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.367% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 85.817% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 68.813% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 92.623% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 98.692% |
| PureTech Health plc | -146.19 Million USD | 99.843% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 98.932% |
| IXICO plc | -1.43 Million USD | 84.03% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 97.582% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.812% |
| CSL Limited | 3.81 Billion USD | 100.006% |
| Cellectis S.A. | -108.85 Million USD | 99.789% |